Immunoreactivities of seven IA-2 constructs in 177 GADA+ LADA patients
| Fragment | IA-2 COOH-terminal domains | IA-2 middle domains | IA-2 constructs utilized in international screenings | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IA-2(761–964) | IA-2PTP (687–979) | IA-2(256–760) | IA-2JM (601–630) | IA-2IC (605–979) | IA-2FL (1–979) | IA-2BDC (256–556:630–979) | |||||
| % A+ | 9.6 | 11.3 | 29.4* | 9.6 | 19.8† | 18.1‡ | 13.0 | ||||
| n A+ (N = 177) | 17 | 20 | 52 | 17 | 35 | 32 | 23 | ||||
* P < 0.0001 vs. IA-2(761–964), IA-2PTP, and IA-2JM; P = 0.048 vs. IA-2IC; P = 0.017 vs. IA-2FL; P < 0.002 vs. IA-2BDC.
† P = 0.01 vs. IA-2(761–964) and IA-2JM; P = 0.039 vs. IA-2PTP.
‡ P = 0.03 vs. IA-2(761–964) and IA-2JM.